Lyvgen Biopharma, a China-based global biotech company, announced on Sunday that it has entered into collaboration with United States-based Bristol Myers Squibb for an open label, phase two, multicentre, randomised trial of LVGN7409 and docetaxel or nivolumab in patients with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC).
LVGN7409, a recombinant monoclonal antibody that targets CD40 for activation optimally in tumour microenvironment, which is a member of the tumour necrosis factor (TNF) receptor family (TNFRSF5) and modulates immune responses by activating antigen presenting cells and reprograming the immuno-suppressive tumour microenvironment.
Bristol Myers Squibb's nivolumab is a human monoclonal antibody that binds to the PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response.
LVGN7409 is a recombinant monoclonal antibody that targets CD40 for activation optimally in tumour microenvironment, which is a member of the tumour necrosis factor (TNF) receptor family (TNFRSF5) and modulates immune responses by activating antigen presenting cells and reprograming the immuno-suppressive tumour microenvironment.
Bristol Myers Squibb's nivolumab, a human monoclonal antibody, binds to the PD-1 and stops its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response.
Docetaxel, an anti-tubulin chemotherapy agent, is utilised to treat various types of cancer, including non-small-cell lung cancer, breast cancer, head and neck cancer, stomach cancer, and prostate cancer.
According to the terms of the contract, Lyvgen is to sponsor the study and Bristol Myers Squibb is to provide nivolumab for the combination trial. Lyvgen will have the global commercial and development rights to LVGN7409.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review